A5049334555- Venomous Animal Envenomation and Studies
- Rabies epidemiology and control
- Inflammatory Bowel Disease
- Eosinophilic Esophagitis
- Microscopic Colitis
- Healthcare and Venom Research
- Amphibian and Reptile Biology
- Gastroesophageal reflux and treatments
- Eosinophilic Disorders and Syndromes
- Helicobacter pylori-related gastroenterology studies
- Pharmaceutical studies and practices
- Marine Invertebrate Physiology and Ecology
- Agricultural Economics and Practices
- Immunodeficiency and Autoimmune Disorders
- Esophageal and GI Pathology
- Veterinary medicine and infectious diseases
- Biosimilars and Bioanalytical Methods
- Monetary Policy and Economic Impact
- Ion channel regulation and function
- Gastric Cancer Management and Outcomes
- Forecasting Techniques and Applications
- Diagnosis and treatment of tuberculosis
- Chronic Lymphocytic Leukemia Research
Indian Institute of Science Bangalore
2023-2024
Takeda (United States)
2020-2023
Centre for Cellular and Molecular Biology
2020-2023
Nirma University
2022
Takeda (United Kingdom)
2019-2020
Maintenance treatment with vedolizumab, a monoclonal antibody that inhibits the gut-selective α4β7 integrin, is administered intravenously. Some patients might prefer subcutaneous formulation of vedolizumab for maintenance treatment. Subcutaneous was investigated as in moderately to severely active ulcerative colitis.We performed phase 3, double-blind, double-dummy trial at 141 sites 29 countries from December 18, 2015 through August 21, 2018. Patients colitis received open-label intravenous...
Abstract Background and Aims To report results from VISIBLE 2, a randomised, double-blind, placebo-controlled, phase 3 trial evaluating new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn’s disease [CD]. Methods Following open-label 300 mg intravenous induction therapy at Weeks 0 Week 6 clinical responders (≥70-point decrease CD Activity Index [CDAI] score baseline) were randomised 2:1 receive double-blind 108 SC or...
To date, there are no systematic pharmacokinetic [PK] data on vedolizumab in paediatric inflammatory bowel disease [IBD]. We report results from HUBBLE, a dose-ranging, phase 2 trial evaluating the PK, safety and efficacy of intravenous for IBD.Enrolled patients [aged 2-17 years] with moderate to severe ulcerative colitis [UC] or Crohn's [CD] body weight ≥10 kg were randomized by receive low- high-dose [≥30 kg, 150 300 mg; <30 100 200 mg] Day 1 Weeks 2, 6 14. Week 14 assessments included...
Aims Helicobacter pylori (Hp) eradication plays a key role in the treatment and prevention of peptic ulcer diseases. Increasing clarithromycin resistance Hp necessitates more effective treatments for eradication, such as bismuth‐containing quadruple therapy. We aimed to compare safety pharmacokinetics (PK) bismuth between vonoprazan‐ lansoprazole‐containing therapy Hp‐positive subjects. Methods In this randomised, double‐blind, parallel‐group study, subjects were randomised receive or Each...
Summary Background Questions remain regarding the safety of swallowed topical corticosteroids in eosinophilic oesophagitis (EoE). Aim To assess an investigational formulation budesonide (budesonide oral suspension; BOS) from six trials. Methods Safety data were integrated trials (healthy adults: SHP621‐101 [phase 1]; patients with EoE: MPI 101‐01 and 101‐06 2]; SHP621‐301, SHP621‐302 SHP621‐303 3]) for participants who received ≥1 dose study drug (BOS 2.0 mg twice daily [b.i.d.], BOS any...
Snakebite is a socio-economic problem in tropical countries and it exacerbated by geographical venom variation of snakes. We investigated on geographically distinct populations Echis carinatus from three ecologically regions: Tamil Nadu (ECVTN), Goa (ECVGO), Rajasthan (ECVRAJ). Venom was fractionated RP-HPLC, combined with SDS-PAGE, subjected to tandem mass spectrometry. Toxins were identified, their relative abundance estimated. Using NCBI database genus, we queried the MS/MS spectra, found...
Snake envenoming is caused by many biological species, rather than a single infectious agent, each with multiplicity of toxins in their venom. Hence, developing effective treatments challenging, especially biodiverse and biogeographically complex countries such as India. The present study represents the first genus-wide proteomics analysis venom composition across Naja species (N. naja, N. oxiana, kaouthia) found mainland Venom proteomes were consistent between individuals from same...
Snake venoms can exhibit remarkable inter- and intraspecific variation. While diverse ecological environmental factors are theorised to explain this variation, only a handful of studies have attempted unravel their precise roles. This knowledge gap not impedes our understanding venom evolution but may also dire consequences on snakebite treatment. To address shortcoming, we investigated the evolutionary ecology Russell's viper (Daboia russelii) spectacled cobra (Naja naja), India's two...
In India, polyvalent antivenom is the mainstay treatment for snakebite envenoming. Due to batch-to-batch variation in production, manufacturers have estimate its efficacy at each stage of IgG purification using median effective dose which involves 100–120 mice batch. There an urgent need replace excessive use animals snake production vitro alternatives. We tested a single batch from VINS bioproducts limited on Echis carinatus venom collected three different locations—Tamil Nadu (ECVTN), Goa...
Abstract Background Vedolizumab (VDZ) is a gut-selective, humanised, monoclonal α 4β 7 integrin antibody for the treatment of patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). VDZ currently an intravenous (IV) therapy; subcutaneous (SC) formulation under development provide alternative route administration maintenance UC and CD. Here we present first data from phase 3 study SC in Methods VISIBLE 2 (NCT02611817; EudraCT 2015-000481-58) was...
INTRODUCTION: Vedolizumab (VDZ) is a gut-selective, humanized, monoclonal antibody against α4β7 integrin currently available as an intravenous (IV) infusion and approved to treat moderately severely active ulcerative colitis (UC) Crohn's disease (CD). The efficacy safety of subcutaneous (SC) formulation were evaluated maintenance therapy in patients with UC (VISIBLE 1) CD 2) (1,2). METHODS: ongoing VISIBLE open-label extension (OLE) multinational, multicenter, phase 3 study...
Snakebite is a major public health concern in many parts of the world, including India, where over 58,000 deaths occur annually due to snake envenoming. The common krait ( Bungarus caeruleus ) responsible for second-highest number snakebite-related mortalities country. However, despite its notoriety, little known about venom ecology, functions and compositional variation across bioclimatic zones, partly because these nocturnal snakes are highly elusive, making it difficult find them wild. We...
Okra (Abelmoschus Esculentus) is perishable in nature and its variable prices as well arrivals depend on the supply demand market.Approximately 73% of worldwide cultivated India.This research incorporates seasonal variation forecasting three categories prices, which were deseasonalized to achieve a regression line.Initial values level, trend seasonality exploited from line used perform static time series analysis.The same initial then updated for every new data entry adaptive model (Winters...
Introduction: Budesonide oral suspension (BOS) is an immediate-release swallowed topical corticosteroid developed for eosinophilic esophagitis (EoE). We present integrated safety analysis of all clinical trials BOS to provide the largest set data on a EoE date. Methods: Data were pooled from 6 (phase 1, SHP621-101; phase 2, MPI 101-01, 101-06; 3, SHP621-301, SHP621-302 and SHP621-303) participants who received ≥1 dose (any trial) or induction placebo (MPI 101-01/MPI 101-06/SHP621-301). For...